Frequently Asked Questions
The market is segmented based on , By Drugs (Aminocaproic Acid, Tranexamic Acid, Others), Indication (Gynecology, Gastrointestinal Bleeding, Hereditary Angioedema, Hemorrhage, Surgeries, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
.
The Global Antifibrinolytic Market size was valued at USD 15.00 USD Billion in 2021.
The Global Antifibrinolytic Market is projected to grow at a CAGR of 5% during the forecast period of 2022 to 2029.
The major players operating in the market include Pfizer, F. Hoffmann La Roche, Mylan, Fresenius Kabi, Novartis, Teva Pharmaceutical Industries, Bristol Myers Squibb, GSK, Bayer, Sun Pharmaceuticals Industries, Amneal Pharmaceuticals, Alvogen, Akorn, DAIICHI SANKYO COMPANY.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
